Clinical trial readout dates for Edgewise Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 2 Sevasemten 10 mg Becker Muscular Dystrophy · NCT05291091 | September 2026 Primary data collected |
| Phase 2 Sevasemten Dose 1 Duchenne Muscular Dystrophy · NCT05540860 | January 2027 Ongoing |
| Phase 2 Sevasemten Dose 1 Duchenne Muscular Dystrophy · NCT06100887 | March 2027 Ongoing |
| Phase 2 EDG-15400 25 mg Heart Failure With Preserved Ejection Fraction · NCT07795814 | December 2027 Recruiting |
| Phase 2 EDG-7500 Hypertrophic Cardiomyopathy · NCT06347159 | December 2027 Ongoing |
| Phase 2 Sevasemten Becker Muscular Dystrophy · NCT06066580 | February 2031 Enrolling |
Edgewise Therapeutics Inc. reported $1.74B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). It reported net income of $1.17B for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |